Browse our 650+ Publications​

Latest Publications

Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease

Parsons E et al.
Frontiers in Immunology
January 2026
Authors and Affiliates
Emily Parsons, Zhongyan Lu, Stephanie A. Richard, Amanda Zelkoski, Janifer Le, Naraen Palanikumar, Phuong Nguyen, Camille Alba, Gauthaman Sukumar, John Rosenberger, Xijun Zhang, Timothy H. Burgess, Rhonda Colombo, Katrin Mende, Catherine Berjohn, Nursat Epsi, Brian K. Agan, David Tribble, David A. Lindholm, Clifton L. Dalgard, Simon D. Pollett, Allison M. W. Malloy* and EPICC COVID-19 Cohort Study Group

Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.

Miller et al.
BMJ
January 2026
Authors and Affiliates
Natalie J Miller, Christina Baik, Joel W Neal, Fangdi Sun, Rafael Santana-Davila, Sylvia Lee, Keith D Eaton, Renato G Martins, Cristina Rodriguez, Heather Wakelee, Sukhmani K Padda, Elena Sotillo, Eric Q Konnick, Alex Camai, Tatyana Pisarenko, Viswam S Nair, Crystal Mackall, A McGarry Houghton, Shin-Heng Chiou, Diane Tseng

HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

Zhang BC, et al.
EBio Medicine
September 2025
Authors and Affiliates
Brian C. Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik Yusko, Damon May, Daniel Mattox, Eva Dawin, Lisa Ann Gerdes, Florence Bucciarelli, Lisa Revie, Gisela Antony, Sven Jarius, Christiane Seidel, Makbule Senel, Stefan Bittner, Felix Luessi, Joachim Havla, Matthias Knop, Manuel A. Friese, Susanne Rothacher, Anke Salmen, Fumie Hayashi, Roland Henry, Stacy Caillier, Adam Santaniello, University of California San Francisco MS-EPIC Team, German Competence Network Multiple Sclerosis (KKNMS), Maria Seipelt, Christoph Heesen, Sandra Nischwitz, Antonios Bayas, Hayrettin Tumani, Florian Then Bergh, Gerd Meyer zu Hörste, Tania Kümpfel, Catharina C. Gross, Brigitte Wildemann, Martin Kerschensteiner, Ralf Gold, Sven G. Meuth, Frauke Zipp, Bruce A. C. Cree, Jorge Oksenberg, Michael R. Wilson, Stephen L. Hauser, Scott S. Zamvil, Luisa Klotz, Roland Liblau.

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 | Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 | David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 | David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 | Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1 1University of Chicago, Chicago, Illinois, USA 2Department of Hematology, Medical University of Lodz, Łódź, Poland 3Adaptive Biotechnologies, Seattle, Washington, USA 4Poznan University of Medical Sciences, Poznan, Poland 5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA 6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA 7Endeavor Health, Evanston, Illinois, USA 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 9University of Colorado, Denver, Colorado, USA

Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis

Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2, Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3, Giada Bianchi1,2,3* 1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators Clinica São Germano, São Paulo, Brazil (V Hungria MD); Medical University of Łódź, Łódź, Poland (Prof P Robak MD); Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland (Prof M Hus MD, M Mielnik MD); Gorodskaya Klinicheskaya Bol’nitsa Im Sp Botkina, Moscow, Russia (V Zherebtsova MD); Royal North Shore Hospital, Sydney, NSW, Australia (Prof C Ward MD); Royal Prince Alfred Hospital, Camperdown, NSW, Australia (Prof P J Ho MBBS); University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic (Prof R Hájek MD); Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea (Prof K Kim MD); Medical University of Silesia, Katowice, Poland (Prof S Grosicki MD); Pindara Private Hospital, Gold Coast, QLD, Australia (H Sia MBBS); Liverpool Hospital, Sydney, NSW, Australia (A Bryant PhD); Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil (Prof M Pitombeira de Lacerda MD); Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil (G A Martinez MD); Institut Català d’Oncologia- L’Hospitalet L.-Barcelona, Barcelona, Spain (A Sureda Balarí MD); Cross Cancer Institute, Edmonton, AB, Canada (I Sandhu MD); Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST IRCCS, Meldola, Forlì-Cesena, Italy (C Cerchione MD); Christchurch Hospital, Christchurch, New Zealand (P Ganly PhD); School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (Prof M A Dimopoulos MD); Korea University, Seoul, South Korea (Prof M A Dimopoulos); The First Affiliated Hospital of Soochow University, Jiangsu, China (Prof C Fu MD); University Hospitals of Leicester NHS Trust, Leicester, UK (M Garg MD); University of Kansas Cancer Center, Fairway, KS, USA (A-O Abdallah MD); Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M E Gatt MD); Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain (A Oriol Rocafiguera MD); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Prof M Cavo MD); Rocky Mountain Cancer Centers— Denver—Midtown, Denver, CO, USA (R Rifkin MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); GSK, Collegeville, PA, USA (J Ficek PhD, A Mantero PhD, N Pirooz MHA, S Varghese MBBS, R Rogers MS, S Roy-Ghanta MD, P Mukhopadhyay PhD, J Opalinska MD); GSK, London, UK (J Lee PhD, L Eccersley PhD); GSK, Stevenage, UK (A McKeown PhD); GSK, Mississauga, ON, Canada (H Baig BS); GSK, Chicago, IL, USA (J Nielsen PhD); Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca– IBSAL–CIC–Ciberonc, Salamanca, Spain (M-V Mateos MD)

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif, Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk, Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab, Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan
Previous Next